ENLV, IL0011319527

Enlivex cuts workforce 60 percent as Allocetra trial tests Enlivex stock

Published on 10/22/2026 at 14:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Enlivex expects mid-2027 Phase 2b data after a 60 percent workforce cut. Enlivex stock costs EUR 0.19 on October 22, 2026.

Trial focus and dates

Enlivex announced a 60 percent workforce reduction on October 19, 2026.
The company expects six-month Phase 2b data by mid-2027.
Enlivex stock was trading at EUR 0.19 at 2:17 p.m. CEST at Lang & Schwarz on October 22, 2026.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex (ISIN IL0011319527) is cutting its workforce by 60 percent to concentrate resources on the Phase 2b Allocetra trial for age-related knee osteoarthritis. According to GlobeNewswire reported on October 19, 2026 that Enlivex would wind down research and development unrelated to the trial, reduce management salaries by 20 percent and cut the chief executive officer's compensation by 40 percent.

What does the cost cut change?

The plan shifts the company's operating emphasis from a broader research program to clinical execution. Enlivex expects topline six-month Phase 2b data by mid-2027, creating a defined milestone for the Allocetra program. The study evaluates intra-articular injections in patients aged 64 and older with moderate-to-severe age-related symptomatic primary knee osteoarthritis, according to the October 19 release.

The financial backdrop makes the restructuring material. In the six months ended June 30, 2026, Enlivex reported USD 1,949.047 million of GAAP net income versus a USD 5.320 million net loss in the prior-year period, while operating loss widened to USD 15.828 million from USD 6.611 million. StockTitan reported that the net income largely reflected unrealized fair-value gains from digital assets and the RAIN Option, rather than clinical operating revenue.

Three milestones shape the story

On July 30, 2026, Enlivex said RAIN protocol trading volume reached USD 860 million, up 622 percent month over month, according to the company's investor update. On September 22, 2026, the company announced the termination of one previously announced financing payable in RAIN tokens. On October 19, 2026, the workforce reduction and Phase 2b focus became the latest operating milestone.

Which dates matter next?

EarningsToday lists November 13, 2026 as the next scheduled reporting date. The company expects the next major clinical readout by mid-2027.

Stock price and clinical focus

For investors, the cost plan creates a clearer trade-off: lower operating spending is paired with dependence on one leading clinical program and a volatile digital-asset treasury. Enlivex's six-month results show why the headline profit figure requires careful interpretation.

Enlivex stock was trading at EUR 0.19 at Lang & Schwarz on October 22, 2026 at 2:17 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Enlivex stock.